Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Shanghai Fosun Pharmaceutical (Group) Co ( (HK:2196) ) has shared an update.
Shanghai Fosun Pharmaceutical announced the resignation of Mr. Wu Yifang as a non-executive director due to personal work reassignment, effective September 30, 2025. The company proposed the appointment of Mr. Liu Yi as an executive director, subject to shareholder approval. Mr. Liu, currently the CEO and president of the company, has extensive experience in medical devices and diagnostics, and holds several leadership roles within the company and its subsidiaries.
The most recent analyst rating on (HK:2196) stock is a Buy with a HK$35.30 price target. To see the full list of analyst forecasts on Shanghai Fosun Pharmaceutical (Group) Co stock, see the HK:2196 Stock Forecast page.
More about Shanghai Fosun Pharmaceutical (Group) Co
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. is a joint stock company incorporated in China, focusing on the pharmaceutical and healthcare industry. It operates through various subsidiaries, providing medical devices, diagnostics, and biotech solutions, and is listed on the Hong Kong Stock Exchange.
Average Trading Volume: 11,635,533
Technical Sentiment Signal: Buy
Current Market Cap: HK$81.13B
For an in-depth examination of 2196 stock, go to TipRanks’ Overview page.